A synthetic biology-based device prevents liver injury in mice

Peng Bai1, Haifeng Ye1,2, Mingqi Xie1, Pratik Saxena1, Henryk Zulewski1,3,4, Ghislaine Charpin-El Hamri1, Valentín Djonov6, Martin Fussenegger1,7,∗

1Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland; 2Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Dongchuan Road 500, Shanghai 200241, China; 3Faculty of Medicine, University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland; 4Division of Endocrinology and Diabetes, Stadtspital Triemli, Birmensdorferstrasse 497, CH-8063 Zurich, Switzerland; 5Département Génie Biologique, Université Claude Bernard 1, 43 Boulevard du 11 Novembre 1918, F-69100 Villeurbanne, France; 6Institute of Anatomy, University of Berne, Baltzerstrasse 2, CH-3000 Berne, Switzerland; 7Faculty of Science, University of Basel, Mattenstrasse 26, CH-4058 Basel, Switzerland

Background & Aims: The liver performs a panoply of complex activities coordinating metabolic, immunologic and detoxification processes. Despite the liver’s robustness and unique self-regeneration capacity, viral infection, autoimmune disorders, fatty liver disease, alcohol abuse and drug-induced hepatotoxicity contribute to the increasing prevalence of liver failure. Liver injuries impair the clearance of bile acids from the hepatic portal vein which leads to their spill over into the peripheral circulation where they activate the G-protein-coupled bile acid receptor TGR5 to initiate a variety of hepatoprotective processes.

Methods: By functionally linking activation of ectopically expressed TGR5 to an artificial promoter controlling transcription of the hepatocyte growth factor (HGF), we created a closed-loop synthetic signalling network that coordinated liver injury-associated serum bile acid levels to expression of HGF in a self-sufficient, reversible and dose-dependent manner.

Results: After implantation of genetically engineered human cells inside auto-vascularizing, immunoprotective and clinically validated alginate-poly-(L-lysine)-alginate beads into mice, the liver-protection device detected pathologic serum bile acid levels and produced therapeutic HGF levels that protected the animals from acute drug-induced liver failure.

Conclusions: Genetically engineered cells containing theranostic gene circuits that dynamically interface with host metabolism may provide novel opportunities for preventive, acute and chronic healthcare.

Keywords: Genetically engineered cells; Gene- and cell-based therapy; Liver disease; Regeneration; Synthetic biology; Synthetic gene circuits.

Received 9 October 2015; received in revised form 9 March 2016; accepted 17 March 2016; available online 9 April 2016
∗Corresponding author. Address: Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland. Tel.: +41 61 387 31 60; fax: +41 61 387 39 88. E-mail address: fussenegger@bsse.ethz.ch (M. Fussenegger).

Abbreviations: HGF, hepatocyte growth factor; PKA, cAMP-dependent phosphokinase A; CRE, cAMP-response element; PCRE, CRE-containing synthetic mammalian promoter; SEAP, human placental secreted alkaline phosphatase; CREm, modified cAMP-response element; PCREm, modified PCRE variant; TUDCA, tauroursodeoxycholic acid; shGLP1, short human glucagon-like peptide 1; SBA, serum bile acid; CCl4, Carbon tetrachloride; ANIT, alpha-naphthylisothiocyanate.

Introduction

The liver is associated with over 500 functions which include the clearance of the blood from toxic compounds, drugs and infectious agents, the control of blood fat and glucose levels, and the recovery, processing and conversion of digested food into metabolic energy [1]. The processing of digested food requires the production of bile and its major component, the bile acids. Bile acids are synthesized from cholesterol in the liver, secreted by the hepatocytes into bile canaliculi and stored in the gallbladder [2]. After each meal, bile acids are released into the duodenum to emulsify ingested fats and other lipophilic nutrients, reabsorbed in the terminal ileum and transported back to the liver via the portal vein, a process known as enterohepatic circulation [2,3]. Efficient clearance and recycling of bile acids from the portal vein ensures low bile acid levels in the peripheral circulation, which increase only marginally after each meal [2]. However, in patients suffering from diverse liver diseases such as cirrhosis, cholestasis, hepatitis and liver cancer, fasting blood bile acid levels are markedly increased due to the impaired hepatic clearance of bile acids from the portal vein [4–10]. Serum bile acid (SBA) levels therefore serve as sensitive indicator of liver disease [4–10]. Because of the minor daily meal-based fluctuations and their excessive levels during liver-associated pathologies, SBAs have been suggested to play a more prominent metabolic role exceeding the one of emulsifying nutrients [2,11].

Indeed, bile acids have recently emerged as versatile signalling compounds endowed with systemic endocrine function.
Bile acids are ligands of several nuclear hormone receptors such as farnesoid X receptor (FXR) and G-protein-coupled receptors (GPR) such as TGR5 through which they activate diverse signalling pathways that regulate triglyceride, cholesterol, glucose and energy homeostasis as well as their own synthesis, enterohepatic circulation, inflammation and liver regeneration [2,11]. In particular, bile acid-mediated activation of TGR5 coordinates renal clearance of bile acids, thereby preventing toxic bile acid overload [11,12]. In addition, pro-inflammatory mediators induce the production of hepatocyte growth factor (HGF), which has a potent cytoprotective impact on hepatocytes, triggers their proliferation and stimulates migration and proliferation of activated hepatic stromal cells into the liver parenchyma, where the cells differentiate into mature hepatocytes [13–15].

Liver diseases are particularly difficult to diagnose as latent inflammations leading to critical fibrosis, irreversible cirrhosis and organ failure may go unnoticed as they fail to trigger any symptoms or significant discomfort [16,17]. To date, liver transplantation is the major treatment option for late-stage liver diseases [1]. However, because of the shortage of donor livers, as well as the significant risk associated with transplantation and life-long immunosuppression, a genetically engineered cell-based theranostic liver-protection device combining precise diagnosis of acute liver injuries with targeted therapeutic or hepatoprotective interventions may represent an attractive alternative.

Capitalizing on SBAs as a well-established biomarker for a wide variety of liver-associated pathologies [4–10], TGR5 as a liver injury-specific bile acid sensor and HGF as a promising protein therapeutic validated in human clinical trials [18–21], we have functionally linked these components using a synthetic biology-based design strategy to create a closed-loop synthetic gene network that detects the onset of liver injury, initiates HGF-mediated liver regeneration and prevents liver failure.

Materials and methods

Components of the liver-protection device

Comprehensive design and construction details for all expression vectors are provided in Table 1. The key components of the liver-protection device include pPB2 for constitutive low-level expression of the human bile acid receptor TGR5 (P_hCMV-1-TGR5-pA) and pPB5, which produces human hepatocyte growth factor in a bile acid-responsive TGR5-dependent manner (P_hCMV-HGF-pA).

Cell culture and transfection

Human embryonic kidney cells (HEK-293, ATCC: CRL-11268 [HEK-293T]), baby hamster kidney cells (BHK-21, ATCC: CCL-10), human fibrosarcoma cells (HT-1080, ATCC: CCL-121) and telomerase-immortalised human mesenchymal stem cells (hMSC-TERT, [22]) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA; cat. no. 12400-060) supplemented with 5% (v/v) FBS (Sigma-Aldrich, St. Louis, USA; cat. no. F7002) and 1% (v/v) penicillin/streptomycin. 10% (v/v) fetal bovine serum (FBS; Sigma-Aldrich, Munich, Germany; cat. no. F2001), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA; cat. no. 15140-122) were added to all medium before transfection. 5 · 10^5 cells were cultured in a 12-well plate 1 h before transfection. All cell types were transfected using polyethylenimine (PEI)-based protocol [23]. For transfection of CHO-K1, HEK-293, BHK-21, HT-1080 and hMSC-TERT, 5 · 10^5 cells seeded per well of a 24 well plate 20 h before transfection were incubated with a transfection solution containing 0.55 µg plasmid DNA (for co-transfections equal amounts of plasmid DNA was used) and 2.2 µl of PEI (polyethylenimine: MW=40,000, stock solution 1 µg/µl in ddH2O; Polysciences, Eppelheim, Germany; cat. no. 24765-2). For transfection of suspension FreeStyle™ 293-F cells, 1 · 10^6 cells seeded per well of a 12 well plate 1 h before transfection were incubated with a transfection solution containing 1.1 µg plasmid DNA and 4.4 µl PEI (1 µg/µl). The DNA/PEI transfection solution was mixed with 50 µl 150 mM NaCl, incubated for 15 min at 22 °C and added dropwise to the cells. Cell concentrations were profiled with a CASY® Cell Counter and Analyser System Model TT (Roche Diagnostics GmbH, Mannheim, Germany).

Animal experiments

Intraperitoneal genetically engineered cell implants were produced by encapsulating pHIV4/pSP16 (P_hCMV-1-eYFP-pA/P_hCMV-SEAP-pA), pPB2/pSP16 (P_hCMV-1-TGR5-pA/P_hCMV-SEAP-pA), pPB2/pPB5 (P_hCMV-1-TGR5-pA/P_hCMV-HGF-pA) and pPB7 (P_hCMV-HGF-pA)-transgenic hMSC-293 cells into coherent alginate-poly-(L-lysine)-alginate beads (400 µm; 200 cells/capsule) using an Inotec Encapsulator Research Unit IE-508 (Ruechti Laborteknik AG, Flawil, Switzerland) set to the following parameters: 25 ml syringe operated at a flow rate of 450 units, 200 µm nozzle with a vibration frequency of 1.020 Hz and 1.1 kV for bead dispersion, stirrer speed at 4.5 units. 8 week-old female OF1 mice (oncins France souche 1; Charles River Laboratory, Lyon, France) were intraperitoneally injected with 2–5 · 10^5 cells (700 µl DMEM containing 1–2.5 · 10^5 capsules, 200 cells/capsule) and were treated with bile acids (cholic acid [0–160 mg/kg] or tauroursodeoxycholic acid [0–160 mg/kg], twice-daily intraperitoneal injections of 0–80 mg/kg; cholic acid [0–160 mg/kg] or deoxycholic acid [0–80 mg/kg], twice-daily intravenous injections of 0–80 mg/kg; cholic acid [0–160 mg/kg], twice-daily intraperitoneal injections of 2–5 mg/kg; tauroursodeoxycholic acid [0–40 mg/kg] or deoxycholic acid [0–100 mg/kg], twice or thrice-daily oral administration of 0–40 mg/kg, hepatotoxicants (1-Naphthyl isothiocyanate [75 mg/kg] or carbon tetrachloride [1 ml/kg], single oral dose) or olive oil (8 ml/kg, single oral dose). Blood samples were collected 48 h after treatment and the serum was isolated using BD Microtainer® SST tubes according to the manufacturer’s instructions (centrifugation for 5 min at 10,000 g; Becton Dickinson, Plymouth, UK; cat. no. 369567). All mice were kept on a standard diet (5 kcal % fat; Janvier S.A.S., Le Genest-Saint-Isle, France) unless indicated otherwise. After completion of the experiments, the animals were sacrificed and their liver collected for histological analysis. All experiments involving animals were performed according to the directives of the European Community Council (2010/63/EU), approved by the French Republic (no. 69266309 and no. 69266310; project no. DR2013-01 (v2)) and carried out by Chislaire Charpin-El Hamri and Marie Daoud-El Baba at the University of Lyon, Institut Universitaire de Technologie (IUTA), F69622 Villeurbanne Cedex, France.

Histology

Two days after implantation of microencapsulated pBP2/pPB5-, pPB2/pSP16- or pPB7-transgenic cells and subsequent oral administration of a single dose of ANIT or olive oil, the mice were sacrificed and their livers were explanted. Five representative liver slices (2–3 mm thick) of each animal were fixed in 0.1 M sodium cacodylate buffer (pH 7.4, 540 mOsm; Sigma-Aldrich, St. Louis, USA; cat. no. C2025) containing 2.5X (v/v) glutaraldehyde (ACAR Scientific Ltd, Stansted, UK; cat. no. R1010) and stored at 4 °C until further processing. Tissue blocks of approximately 1 mm³ were cut, rinsed in 0.1 M sodium cacodylate buffer (3 × 10 min, pH 7.4, 340 mOsm) and post-fixed in 0.1 M sodium cacodylate buffer containing 1% (v/v) osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA, USA; cat. no. 19100) at 4 °C for 2 h. The samples were then washed in 0.1 M sodium cacodylate buffer (3 × 10 min, pH 7.4, 340 mOsm), dehydrated by serial incubation in ddH2O containing increasing concentrations of ethanol (70%, 80%, 90%, 95%, 99%, 100%) and embedded in Epon 812 (Fluka, Sigma-Aldrich, Buchs, CH; ca. nos. 45245–45347). One µm thick liver sections were prepared using glass knives, stained with toluidine blue (Fluka, Buchs, CH; cat. no. 89640) and observed using a Zeiss Axioskop 2 (Carl Zeiss MicroImaging, Jena, Germany) microscope. Liver sections were photographed with a Nikon Coolpix P900 camera (Nikon Instruments GmbH, Munich, Germany).

Statistics

Results are expressed as mean ± SEM. Statistical significance of datasets was evaluated by a two-tailed, unpaired Student’s t test using Graphpad Prism V6.0d. p <0.05 was considered significant.
**Results**

**Design and characterization of the synthetic mammalian bile acid sensor**

Bile acid-inducible activation of the human GPCR TGR5 triggers an intracellular signal transduction cascade involving $G_{q/11}$-protein-mediated activation of the plasma membrane-bound adenylate cyclase, which converts ATP into the second messenger cyclic AMP (cAMP) [2]. Upon rewiring of the intracellular AMP surge via cAMP-dependent phosphokinase A (PKA)-mediated activation of the cAMP-response element binding protein (CREB1) to CREB1-specific synthetic promoters ($P_{\text{CRE}}$, $P_{\text{CREm}}$) containing cAMP-response elements (CRE), bile acid levels could be directly coupled to expression of a specific target gene (Fig. 1A).

Initial experiments using different expression platforms ($P_{\text{TGR5}}$, $P_{\text{CREm}}$-TGR5-pA; $P_{\text{PB2}}$, $P_{\text{CREm}}$-TGR5-pA) showed that TGR5 was efficiently transcribed (Supplementary Fig. 1A), produced Human hepatocyte growth factor (HGF) and secreted alkaline phosphatase (SEAP) in Mammalian cells [58].

**Table 1. Plasmids used and designed in this study.**

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Description and cloning strategy</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pBABE-puro</td>
<td>Retroviral expression vector.</td>
<td>[58]</td>
</tr>
<tr>
<td>pcDNA3.1(+)</td>
<td>Mammalian expression vector ($P_{\text{CMV}}$-MCS-pA).</td>
<td>Life Technologies, Carlsbad, CA</td>
</tr>
<tr>
<td>pEYFP-C1</td>
<td>Constitutive EYFP expression vector ($P_{\text{CMV}}$-EYFP-pA).</td>
<td>Clontech, Mountain View, CA</td>
</tr>
<tr>
<td>pSEAP2-Control</td>
<td>Constitutive SEAP expression vector ($P_{\text{SEAP}}$-SEAP-pA).</td>
<td>Clontech, Mountain View, CA</td>
</tr>
<tr>
<td>pCMV-SPORT6</td>
<td>Mammalian expression vector ($P_{\text{CMV}}$-MCS-pA).</td>
<td>Life Technologies, Carlsbad, CA</td>
</tr>
<tr>
<td>pBABE-puro HGF</td>
<td>pBABE-puro containing full-length HGF cDNA.</td>
<td>[59]</td>
</tr>
<tr>
<td>pTGR5</td>
<td>pCMV-SPORT6 containing a constitutive TGR5 expression unit ($P_{\text{CMV}}$-TGR5-pA).</td>
<td>GenBank: BC033625</td>
</tr>
<tr>
<td>pCK53</td>
<td>$P_{\text{CRE}}$-driven SEAP expression vector ($P_{\text{CRE}}$-SEAP-pA).</td>
<td>[60]</td>
</tr>
<tr>
<td>pMF111</td>
<td>$P_{\text{CREm}}$-driven SEAP expression vector ($P_{\text{CREm}}$-SEAP-pA).</td>
<td>[61]</td>
</tr>
<tr>
<td>Mkp37</td>
<td>Constitutive TetR-ELK1 expression vector ($P_{\text{CRE}}$-TetR-ELK1-pA).</td>
<td>[62]</td>
</tr>
<tr>
<td>pSP16</td>
<td>$P_{\text{CRE}}$-driven SEAP expression vector ($P_{\text{CRE}}$-SEAP-pA).</td>
<td>[63]</td>
</tr>
<tr>
<td>pHY57</td>
<td>$P_{\text{CREm}}$-driven shGLP1 expression vector ($P_{\text{CREm}}$-shGLP1-pA).</td>
<td>[31]</td>
</tr>
<tr>
<td>pHY67</td>
<td>$P_{\text{CRE}}$-driven shGLP1 expression vector ($P_{\text{CRE}}$-shGLP1-pA).</td>
<td>Ye et al., unpublished</td>
</tr>
<tr>
<td>pHY74</td>
<td>$P_{\text{CREm}}$-driven EYFP expression vector ($P_{\text{CREm}}$-EYFP-pA).</td>
<td>This work</td>
</tr>
<tr>
<td>pPB2</td>
<td>$P_{\text{CREm}}$-driven TGR5 expression vector ($P_{\text{CREm}}$-TGR5-pA).</td>
<td>This work</td>
</tr>
<tr>
<td>pPB5</td>
<td>$P_{\text{CRE}}$-driven HGF expression vector ($P_{\text{CRE}}$-HGF-pA).</td>
<td>This work</td>
</tr>
<tr>
<td>pPB6</td>
<td>$P_{\text{CREm}}$-driven HGF expression vector ($P_{\text{CREm}}$-HGF-pA).</td>
<td>This work</td>
</tr>
<tr>
<td>pPB7</td>
<td>Constitutive HGF expression vector ($P_{\text{CRE}}$-HGF-pA).</td>
<td>This work</td>
</tr>
<tr>
<td>pPB8</td>
<td>$P_{\text{CREm}}$-driven HGF expression vector ($P_{\text{CREm}}$-HGF-pA).</td>
<td>This work</td>
</tr>
</tbody>
</table>

CRE, cAMP-response element; CREm, modified cAMP-response element; ELK1, ETS domain-containing transcription factor; ETS, E26 transformation-specific or E-twenty-six transcription factor family; EYFP, enhanced yellow fluorescent protein; GC, human hepatocyte growth factor; MCS, multiple cloning site; NFAT, nuclear factor of activated T cells; PA, polyadenylation signal; $P_{\text{CRE}}$, CRE containing synthetic mammalian promoter; $P_{\text{CREm}}$, modified $P_{\text{CRE}}$ variant; PCR, polymerase chain reaction; $P_{\text{CMV}}$, human cytomegalovirus immediate early promoter; $P_{\text{CMV*-1}}$, minimal version of $P_{\text{CMV}}$; $P_{\text{CRE}}$, tetracycline-responsive promoter ($tetO/PhCMV$); $P_{\text{CREm}}$, synthetic mammalian promoter containing a NFAT-response element; $P_{\text{SEAP}}$, simian virus 40 promoter; TGR5, Escherichia coli Tn10-derived tetracycline-dependent repressor of the tetracycline resistance gene; Tol0, TetR-specific heptameric operator sequence; TetR-ELK1, TetR-ELK1 fusion protein; SEAP, human placental secreted alkaline phosphatase; shGLP1, short human glucagon-like peptide 1; TGR5, human bile acid receptor (GenBank: BC033625) also known as GPBAR1 (G protein–coupled bile acid receptor 1) or M-BAR (membrane-type receptor for bile acids).

Oligonucleotides: Restriction endonuclease-specific sites are in italics and annealing base pairs are indicated in capital letters.
Acid sensor was functional in different pPB2-/pSP16-co-transfected mammalian cell lines including human ones, such as, suspension cell lines and stem cells, suggesting that the synthetic signalling cascade was broadly applicable (Fig. 1E). As expected, possible differences in availability and compatibility of the endogenous signal transduction components with TGR5-mediated input resulted in a wide range of induction factors [24]. Since HEK-293 showed the best bile acid-triggered expression performance, this cell line was chosen for all further experiments (Fig. 1E).
Bile acid-inducible transgene expression in mammalian cells

In order to be functional as part of a higher-order closed-loop liver-protection device in vivo the bile acid sensor has to (i) be sufficiently sensitive to detect the major bile-composing native and modified bile acids within their clinically relevant concentrations range, (ii) show rapid response times and induction kinetics to manage protective and curative therapeutic responses preventing liver failure, (iii) provide bile acid dose-dependent therapeutic transgene expression to coordinate the level of liver injury to the level of therapeutic intervention and (iv) deliver reversible control dynamics which enable the design of a closed-loop gene circuit that constantly adapts the therapeutic expression dosing to the course of the liver disease and protects against liver failure through enhanced regeneration.

Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA) including their conjugated (tauro- and glyco-) isomers represent over 95% of the bile acids found in the human serum [26]. Tauroursodeoxycholic acid (TUDCA), a major bile acid in the serum of bears with only trace amounts found in human and mouse sera, has been associated with potent cytoprotective and antidiabetic activities [26–30]. Human cells containing the bile acid sensor (pPB2/pSP16) were able to detect all (non-)conjugated human and bear bile acids within their clinically relevant concentration range and produced a dose-dependent reporter gene expression profile (Supplementary Fig. 3A) with rapid induction kinetics (Supplementary Fig. 3B). As exemplified using CA as trigger bile acid, bile acid sensor-driven expression kinetics could be precisely programmed by the bile acid exposure time (Supplementary Fig. 3C), which confirmed the rapid response time and induction kinetics of the bile acid sensor. In addition, bile acid sensor-driven reporter gene expression was reversible and showed reproducible induction kinetics when repeatedly switched ON and OFF following addition and withdrawal of bile acids (Fig. 1F).

Bile acid-inducible protein production in serum-free suspension cultures

Dose- and time-specific control of product gene expression in bioreactors requires availability of gene switches that are responsive to trigger cues which are generally regarded as safe (GRAS) and licensed by food and healthcare authorities. Desoxycholic acid is a GRAS compound that is clinically licensed by the Food and Drug Administration (FDA) and approved in many countries as an emulsifier for the food industry and could therefore be considered as a product gene expression trigger in a biopharmaceutical manufacturing setting. We have therefore tested desoxycholic acid as trigger compound for the timely induction of the short human glucagon-like peptide 1 (shGLP1), a long-acting insulinogenic hormone engineered for the treatment of type 2 diabetes mellitus [31], in HEK-293-derived serum-free suspension cultures which is currently considered for the production of viral particles for vaccines and gene therapy [32]. In standard bioreactor operation, shGLP1-expression of HEK-293 cells transgenic for pPB2 and either pPB8 (P_Cre-shGLP1-pA) (Fig. 2A) or pHY67 (P_Cre-shGLP1-pA) (Fig. 2B) was tightly repressed until addition of a specific amount of desoxycholic acid which programmed the shGLP1 expression kinetics and final titer of the production culture to specific levels (Fig. 2).

Bile acid-inducible transgene expression in mice

To validate bile acid-inducible transgene expression in vivo, we microencapsulated pPB2/pSP16-transgenic HEK-293 cells into clinically validated, semi-permeable and immunoprotective
alginate-poly-(L-lysine)-alginate beads (Fig. 3A) and implanted them into the peritoneum of mice where they become vascularized and connected to the animal’s bloodstream [33]. When mice received increasing doses of the clinically licensed drugs CA (Cholbam®) (Fig. 3B) or tauroursodeoxycholic acid (TUDCA) (Fig. 3C) by intraperitoneal injection, the implanted genetically engineered cells detected circulating bile acid levels by bile acid dose-dependent TGR5-mediated expression of SEAP (Fig. 3D), which reached the bloodstream and could be profiled in the peripheral circulation of the animals (Fig. 3B, C). Likewise, the SEAP levels in the bloodstream of treated animals could also be modulated by intravenous injection as well as oral administration of CA (Fig. 3E) and deoxycholic acid (Fig. 3F), confirming that the cell implant is fully integrated in the systemic circulation of the host organism and sensitive to physiologically relevant bile acid concentrations.

Fig. 3. Bile acid-inducible transgene expression in mice. (A) SEAP induction profiles of microencapsulated TGR5/PCREm-SEAP HEK-293 cells in vitro. HEK-293 cells were co-transfected with pSP16 (PCREm-SEAP-pA) and either pPB2 (PheCMV-eYFP-pA) or pHY74 (PheCMV-eYFP-pA) and microencapsulated into alginate-poly-(L-lysine)-alginate beads. 5 × 10^5 capsules (200 cells/capsule) were cultivated in the presence or absence of CA (100 μM), deoxycholic acid (DCA; 100 μM) or tauroursodeoxycholic acid (TUDCA; 100 μM). SEAP levels in the culture supernatants were scored after 24 h. Data presented are mean ± SD, n > 3. (B, C) Dose-dependent bile acid-inducible SEAP expression in mice. Wild-type mice were intraperitoneally implanted with microencapsulated TGR5/PCREm-SEAP (pPB2/pSP16, 2 × 10^6 cells, 1 × 10^6 capsules, 200 cells/capsule) -transgenic HEK-293 cells and received intraperitoneal injections of different daily doses of CA (B) or tauroursodeoxycholic acid (C). SEAP levels in the bloodstream of treated animals were quantified 24 h and 48 h after the first bile acid administration. The data are shown as the mean ± SEM, statistics by two-tailed t test, n = 6 mice. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. (D) Negative control group. Wild-type mice were intraperitoneally implanted with microencapsulated pHY74/pSP16-transfected HEK-293 control cells (2 × 10^6 cells, 1 × 10^6 capsules, 200 cells/capsule) and received intraperitoneal injections of different daily doses of CA. Serum SEAP levels were quantified in the bloodstream of treated animals after 24 h and 48 h. The data are shown as the mean ± SEM, statistics by two-tailed t test, n = 8 mice. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. (E, F) Dose-dependent bile acid-inducible SEAP expression in mice. Wild-type mice were intraperitoneally implanted with microencapsulated pPB2/pSP16-transfected HEK-293 cells (2 × 10^6 cells, 1 × 10^6 capsules, 200 cells/capsule) and received different daily intravenous or oral doses of cholic acid (CA) (E) or deoxycholic acid (DCA) (F). (i) SEAP and (ii) total bile acid levels in the bloodstream of treated animals were quantified 48 h after the first bile acid administration. The data are shown as the mean ± SEM, statistics by two-tailed t test, n = 6 mice. n.s. (not significant) *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
Research Article

The bile acid sensor detects acute liver injuries in mice

The enterohepatic circulation maintains serum bile acid (SBA) levels below 20 μM in man and mice (Fig. 4A) [4–10]. Liver injuries result in imbalances of the enterohepatic circulation leading to acute and chronically increased SBA concentrations (>20 μM in humans), which correlate with excessive blood alanine aminotransferase (ALT) levels (>30–40 U/L in humans and mice) that serves as the gold standard biomarker of liver injury [34,35]. Carbon tetrachloride (CCl4) and alpha-naphthylisothiocyanate (ANIT) are the reference compounds to replicate human drug-induced hepatotoxicity in mice as they either mediate direct destruction of hepatocytes or induce cholestasis by damaging biliary epithelial cells, respectively [36,37]. When mice implanted with pPB2/pSP16-transgenic HEK-293 cells received oral doses of the hepatotoxicants CCl4 (1 ml/kg) or ANIT (75 mg/kg), SBA and ALT levels immediately rose into the critical range (Fig. 4A, B). The acute liver injury was detected and processed by the implanted genetically engineered cell-based bile acid sensor which coordinated the production, secretion and release of the reporter protein SEAP into the bloodstream of treated animals (Fig. 4C). The biosensor was insensitive to the minor diet-induced SBA fluctuations (Fig. 4D) as well as oral dietary-supplement doses of CA, deoxycholic acid and TUDCA that are expected to be cleared by the first-pass effect of a healthy liver (Fig. 3E, Fig. 3F, Fig. 4D). Therefore, the sensitivity of the genetically engineered cell-based bile acid sensor is well suited to exclusively detect pathologic SBA levels in the event of an acute liver injury.

Validation of a self-sufficient closed-loop liver-protection device in mice

Advanced theranostic gene networks combine precise diagnosis of a pathologic situation with targeted therapeutic intervention in a closed-loop control circuit which prevents or cures a specific disease [38]. Therefore, the design of a liver-protection device requires functional interconnection of the bile acid sensor with expression of a therapeutic protein that can prevent liver failure and restore liver function. The human HGF, a secreted protein associated with tissue protection, organ regeneration and wound healing, has recently come into the limelight for the treatment of various organ injuries. Unfortunately, the short half-life (<5 min, [39–41]) of HGF in circulation would require repeated high-dose injections which exacerbates its use as a biopharmaceutical for the time being. However, human clinical trials have shown that in situ production of HGF using a gene therapy approach may provide the full scope of HGF’s therapeutic potential [18–21].

We have therefore linked SBA-triggered activation of TGR5 (pPB2, pCMV-1-TGR5-pA) to PCREm-driven expression of HGF (pPB5, PCREm-HGF-pA). In vitro validation of pPB2/pPBS-transgenic HEK-293 cells confirmed that the genetically engineered cells were able to secrete clinically relevant levels (Supplementary Fig. 4A) of bioactive HGF (Supplementary Fig. 4B) in response to liver-injury-associated bile acid concentrations. When implanting the same cells into mice, the animals were protected from ANIT-induced liver failure and showed significantly reduced blood values of ALT activity (Fig. 5A), SBA levels (Fig. 5B) or bilirubin concentration (Fig. 5C), while the serum levels of all these liver injury-specific biomarkers were dramatically increased in mice treated with placebo implants. Most importantly, the liver-protection device drove high-level HGF expression of a therapeutic protein that can prevent liver failure and restore liver function. The human HGF, a secreted protein associated with tissue protection, organ regeneration and wound healing, has recently come into the limelight for the treatment of various organ injuries. Unfortunately, the short half-life (<5 min, [39–41]) of HGF in circulation would require repeated high-dose injections which exacerbates its use as a biopharmaceutical for the time being. However, human clinical trials have shown that in situ production of HGF using a gene therapy approach may provide the full scope of HGF’s therapeutic potential [18–21].

We have therefore linked SBA-triggered activation of TGR5 (pPB2, pCMV-1-TGR5-pA) to PCREm-driven expression of HGF (pPB5, PCREm-HGF-pA). In vitro validation of pPB2/pPBS-transgenic HEK-293 cells confirmed that the genetically engineered cells were able to secrete clinically relevant levels (Supplementary Fig. 4A) of bioactive HGF (Supplementary Fig. 4B) in response to liver-injury-associated bile acid concentrations. When implanting the same cells into mice, the animals were protected from ANIT-induced liver failure and showed significantly reduced blood values of ALT activity (Fig. 5A), SBA levels (Fig. 5B) or bilirubin concentration (Fig. 5C), while the serum levels of all these liver injury-specific biomarkers were dramatically increased in mice treated with placebo implants. Most importantly, the liver-protection device drove high-level HGF expression of a therapeutic protein that can prevent liver failure and restore liver function. The human HGF, a secreted protein associated with tissue protection, organ regeneration and wound healing, has recently come into the limelight for the treatment of various organ injuries. Unfortunately, the short half-life (<5 min, [39–41]) of HGF in circulation would require repeated high-dose injections which exacerbates its use as a biopharmaceutical for the time being. However, human clinical trials have shown that in situ production of HGF using a gene therapy approach may provide the full scope of HGF’s therapeutic potential [18–21].

We have therefore linked SBA-triggered activation of TGR5 (pPB2, pCMV-1-TGR5-pA) to PCREm-driven expression of HGF (pPB5, PCREm-HGF-pA). In vitro validation of pPB2/pPBS-transgenic HEK-293 cells confirmed that the genetically engineered cells were able to secrete clinically relevant levels (Supplementary Fig. 4A) of bioactive HGF (Supplementary Fig. 4B) in response to liver-injury-associated bile acid concentrations. When implanting the same cells into mice, the animals were protected from ANIT-induced liver failure and showed significantly reduced blood values of ALT activity (Fig. 5A), SBA levels (Fig. 5B) or bilirubin concentration (Fig. 5C), while the serum levels of all these liver injury-specific biomarkers were dramatically increased in mice treated with placebo implants. Most importantly, the liver-protection device drove high-level HGF...
production exclusively following ANIT-triggered increase of SBA levels (Fig. 5D). Histological analysis of the liver of treated animals corroborated the finding that the liver-protection device was able to prevent drug-induced hepatotoxicity: Mice containing the liver-protecting genetically engineered cell implant showed no signs indicative of parenchymal necrosis and inflammatory cell infiltrations that are typically observed following liver injury (Fig. 6; Supplementary Fig. 5).

Discussion

Synthetic biology, the engineering science of reassembling standardized biological parts in a systematic, rational and predictable manner to program novel cellular behaviour, has enabled the design of theranostic circuits that seamlessly couple biosensor-based detection of disease metabolites to an automated and self-sufficient expression of therapeutic transgenes [38,42–44]. By functionally interconnecting the bile acid sensor TGR5 via a synthetic signalling cascade to a modified promoter and expression of the biopharmaceutical HGF, we have designed a theranostic liver-protection device that enables genetically engineered cells to interface with the host metabolism by constantly measuring SBA levels. Whenever SBA levels reach a critical concentration indicative of liver damage, the liver-protection device coordinated the production of HGF in a closed-loop manner by matching diagnosis of liver injuries with liver-protecting therapy. Importantly, the human TGR5 receptor used as the sensor component for the liver-protection device is sensitive to a variety of endogenous serum bile acids within their clinically relevant concentration range and drives expression of therapeutic HGF levels exclusively at pathologic SBA levels. Since TGR5 is also responsive to the potential antidiabetic drug TUDCA, the bile acid sensor might also be used in future gene therapy applications that couple drug-based diabetes therapy with expression of complementary biopharmaceuticals [45].

Drug-induced hepatotoxicity remains a major challenge in the treatment of various diseases such as multidrug-resistant tuberculosis [46] and colorectal cancer [47]. 20% of the patients diagnosed with colorectal cancer have distant metastases, primarily in the liver. Surgical resection of isolated liver metastases is the treatment of choice [48]. When the metastases are too big for primary surgical resection patients are first treated with chemotherapeutic drugs aiming for size reduction that could render them resectable [49]. However, this approach is limited by the hepatotoxicity of the chemotherapeutic agents such as Irinotecan or Oxaliplatin, which may trigger chemotherapeutic-associated steatohepatitis, vascular injury and non-cirrhotic portal hypertension [50]. The liver-protection device may protect...
the liver during the treatment of patients with higher doses of chemotherapeutics.

Drug-induced hepatotoxicity is an important concern in the treatment of tuberculosis, in particular multidrug-resistant tuberculosis, whose prevalence has reached 20% of treated cases [46]. The first-line treatment of this infectious disease includes Isoniazid and Rifampicin, which are hepatotoxic especially when administered at higher doses [51,52]. Indeed, liver failure associated with anti-tuberculosis treatment is the most common acute drug-associated liver failure in South Asia [53]. HGF has been shown to exert liver-protective effects against Isoniazid- and Rifampicin-induced liver damage [54]. The use of a liver-protection device that reversibly triggers the production and secretion of HGF in response to developing liver damage by sensing bile acids may enable the use of anti-tuberculosis drugs at higher doses while limiting the damage to the liver.

The poor pharmacokinetics of HGF so far precludes the use of this potent biopharmaceutical. In situ production of HGF using a gene therapy-based approach has in principle confirmed HGF’s potential for the treatment of liver injuries and other organ insufficiencies such as diabetic neuropathy, critical limb ischemia and ischemic cardiac disease [18–21,55]. However, the classic gene-based treatment strategy lacks the expression dynamics and interface with the host metabolism that is required to adapt HGF production to the disease course in real time. Additionally, chronic activation of the HGF receptor is associated with a variety of cancer types [56,57], which highlights the importance of a self-sufficient HGF production provided by the closed-loop liver-protection device when targeting potentially fatal hepatotoxic drug effects.

Although the liver-protection device exclusively contains human genetic components, is engineered into human cells, and responds to clinically relevant SBA levels, there are still several translational challenges before genetically engineered theranostic cells will be routinely used for human therapy. To adapt genetically engineered theranostic cells to the clinic, critical design parameters will have to be addressed, including the use of autologous cells, scaling of the system to provide therapeutic levels of HGF, and development of an implant that stores the genetically engineered cells in a single device. The final therapy may be based on patient-derived autologous cell batches that are produced, engineered with the liver-protection device, validated for optimal patient-specific response and dosing performance and frozen for storage. The genetically engineered cells will be filled into appropriate containers and implanted into the body where they automatically connect to the bloodstream [33], monitor SBA levels and corresponding liver damage and coordinate the therapeutic response. The genetically engineered cell implants will be preferably placed subcutaneously, since they can be removed by a minimal ambulant intervention in case of complications or replaced at regular intervals (e.g., every 3–4 months) due to fibrosis.

In summary, protection of the liver from drug-induced toxicities by an engineered theranostic liver-protection device may enable novel and/or more aggressive treatments of diseases where the use of current armamentarium is limited by severe hepatic toxicity.

Financial support

This work was supported by a European Research Council advanced grant (ProNet, no. 321381), a personal fellowship by the Chinese Scholarship Council to Peng Bai and in part by the National Centre of Competence in Research Molecular Systems Engineering.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Authors’ contributions

P.B., M.X., H.Y., V.D. and M.F. designed the project. P.B., M.X., H.Y., P.S., H.Z., V.D. and M.F. analysed the results and wrote the manuscript. P.B., V.D. and G.C.E.H. performed the experimental work.
Acknowledgments

We thank Heather Lawrence and Steven Kliwer for providing pTGR5, Ted Abel for providing MKp37, Werner Graber for the excellent technical and microscopy work and Marie Daudel Baba for support with the animal study.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jhep.2016.03.020.

References

Author names in bold designate shared co-first authorship


